OncoMatch/Clinical Trials/NCT05849129
Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
Is NCT05849129 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ascorbic acid for lung cancer.
Treatment: Ascorbic acid — This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization
Cannot have received: immunotherapy
Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization
Cannot have received: IVC
Previously received IVC within 6 months prior to randomization
Lab requirements
Kidney function
egfr >= 45 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify